Longeveron Inc. Files 8-K for Other Events
Ticker: LGVN · Form: 8-K · Filed: Jul 10, 2024 · CIK: 1721484
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
Longeveron filed an 8-K, likely containing important updates. Check for details.
AI Summary
Longeveron Inc. filed an 8-K on July 10, 2024, to report other events and financial statements. The filing does not detail specific transactions or financial results but serves as a notification of these items being filed.
Why It Matters
This filing indicates that Longeveron Inc. has submitted important corporate updates and financial information to the SEC, which may contain material information for investors.
Risk Assessment
Risk Level: low — This 8-K filing is procedural and does not disclose specific negative events, market changes, or financial distress.
Key Players & Entities
- Longeveron Inc. (company) — Registrant
- July 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Miami, Florida (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Longeveron Inc. in this 8-K filing?
The filing indicates 'Other Events' are being reported, but the provided text does not specify the nature of these events.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 10, 2024.
What is Longeveron Inc.'s principal executive office address?
Longeveron Inc.'s principal executive offices are located at 1951 NW 7th Avenue, Suite 520, Miami, Florida 33136.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Longeveron Inc.'s IRS Employer Identification Number?
Longeveron Inc.'s IRS Employer Identification Number is 47-2174146.
Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-07-10 08:00:33
Key Financial Figures
- $0.001 — ich registered Class A Common Stock, $0.001 par value per share LGVN The Nasd
Filing Documents
- ea0209181-8k_longeveron.htm (8-K) — 26KB
- ea020918101ex99-1_longeveron.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-060281.txt ( ) — 223KB
- lgvn-20240710.xsd (EX-101.SCH) — 3KB
- lgvn-20240710_lab.xml (EX-101.LAB) — 33KB
- lgvn-20240710_pre.xml (EX-101.PRE) — 22KB
- ea0209181-8k_longeveron_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events On July 10, 2024, Longeveron Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation for the Company's lead investigational product Lomecel-B TM , an allogeneic Medicinal Signaling Cells formulation sourced from the bone marrow of young, healthy adult donors, for the treatment of mild Alzheimer's disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K. Exhibit No. Description 99.1 Press Release issued by the Company on July 10, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LONGEVERON INC. Date: July 10, 2024 /s/ Wa'el Hashad Name: Wa'el Hashad Title: Chief Executive Officer 2